Abbott stock drops despite Q1 EPS/revenue beat as guidance focus returns
Abbott Laboratories shares fell about 3% after it reported Q1 2026 results around expectations (EPS $1.15 on revenue $11.16B) but investors focused on guidance and segment mix rather than the beat. The move comes as the stock heads into its April 16 earnings call with lingering concern about Diagnostics pressure and the timing/impact of the planned Exact Sciences acquisition closing in Q2 2026.
1. What’s moving the stock
Abbott Laboratories (ABT) slid about 3% in U.S. trading as investors reacted to the company’s Q1 2026 earnings release and reset expectations around the rest of 2026. While headline figures showed a modest beat versus estimates (adjusted EPS $1.15 vs. $1.14 and revenue $11.16B vs. $11.01B), trading indicated the market was more sensitive to forward-looking signals, including guidance trajectory and the mix of growth across segments. (benzinga.com)
2. Why a “beat” can still sell off
A small earnings beat doesn’t always translate into upside when the stock is pricing in stronger acceleration, or when investors believe underlying segment trends are softening. Abbott entered the print with attention on Diagnostics performance and whether management would signal a faster rebound, as well as whether FX, pricing, or procurement dynamics (including China volume-based procurement in prior periods) would continue to weigh on margins. Earlier company guidance set a Q1 adjusted EPS range of $1.12 to $1.18, placing the reported $1.15 near the midpoint—supportive, but not a clear re-acceleration signal by itself. (abbott.mediaroom.com)
3. The next catalysts investors are watching
The key near-term driver is management commentary on the Q1 2026 earnings conference call (scheduled for April 16) and any update to full-year targets. Abbott previously projected full-year 2026 adjusted EPS of $5.55 to $5.80 and organic sales growth of 6.5% to 7.5%, and investors are looking for confirmation that these targets remain intact amid shifting demand in Diagnostics and broader healthcare spending trends. Separately, Abbott has said it expects its Exact Sciences acquisition to close in Q2 2026, and traders are focused on integration costs and the contribution timeline for growth and margins. (abbott.mediaroom.com)
4. Bottom line
Today’s pullback looks like a guidance-and-sentiment move more than a single-quarter “miss,” with the market emphasizing what the quarter implies for 2026 execution. If Abbott reiterates (or raises) its 2026 outlook and shows improving Diagnostics trends, the stock could stabilize; if commentary suggests slower recovery or incremental investment/integration pressure, the downside reaction can persist despite the headline beat. (abbott.mediaroom.com)